glp 1 agonist and depression Transformation 2.0: The GLP-1 RAs as Psychiatric Medications? Glucagon-like peptide-1 receptor agonists and

Recent landmark trials, particularly the SELECT study, have provided compelling evidence for cardiovascular benefits in non-diabetic obese patients, potentially reshaping our understanding of obesity treatment paradigms

At these concentrations, the GLP-1 receptor activation is sufficient to engage anti-inflammatory pathways without triggering the gastrointestinal side effects that make full-dose therapy difficult for many patients

Each visit should cover your weight trajectory, side effect management, metabolic markers (periodic lab work), medication adherence, and any new symptoms or concerns

PMID: 39833406

Consequently, governments, payers, and employers are beginning to adopt these agents as core components of preventive and chronic disease management strategies, driving exponential market demand

Omid Mehrpour (MD, FACMT) is a senior medical toxicologist and physician-scientist with over 15 years of clinical and academic experience in emergency medicine and toxicology